Literature DB >> 26209546

Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 2—External Validity and Correlates.

William P Horan1, L Felice Reddy2, Deanna M Barch3, Robert W Buchanan4, Eduardo Dunayevich5, James M Gold4, Steven R Marder2, Jonathan K Wynn2, Jared W Young6, Michael F Green2.   

Abstract

Effort-based decision making has strong conceptual links to the motivational disturbances that define a key subdomain of negative symptoms. However, the extent to which effort-based decision-making performance relates to negative symptoms, and other clinical and functionally important variables has yet to be systematically investigated. In 94 clinically stable outpatients with schizophrenia, we examined the external validity of 5 effort-based paradigms, including the Effort Expenditure for Rewards, Balloon Effort, Grip Strength Effort, Deck Choice Effort, and Perceptual Effort tasks. These tasks covered 3 types of effort: physical, cognitive, and perceptual. Correlations between effort related performance and 6 classes of variables were examined, including: (1) negative symptoms, (2) clinically rated motivation and community role functioning, (3) self-reported motivational traits, (4) neurocognition, (5) other psychiatric symptoms and clinical/demographic characteristics, and (6) subjective valuation of monetary rewards. Effort paradigms showed small to medium relationships to clinical ratings of negative symptoms, motivation, and functioning, with the pattern more consistent for some measures than others. They also showed small to medium relations with neurocognitive functioning, but were generally unrelated to other psychiatric symptoms, self-reported traits, antipsychotic medications, side effects, and subjective valuation of money. There were relatively strong interrelationships among the effort measures. In conjunction with findings from a companion psychometric article, all the paradigms warrant further consideration and development, and 2 show the strongest potential for clinical trial use at this juncture.
© The Author 2015. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  decision making; effort; functional outcome; schizophrenia

Mesh:

Year:  2015        PMID: 26209546      PMCID: PMC4535650          DOI: 10.1093/schbul/sbv090

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  37 in total

Review 1.  Chronic restlessness with antipsychotics.

Authors:  Irene M Bratti; John M Kane; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2007-11       Impact factor: 18.112

2.  From perception to functional outcome in schizophrenia: modeling the role of ability and motivation.

Authors:  Michael F Green; Gerhard Hellemann; William P Horan; Junghee Lee; Jonathan K Wynn
Journal:  Arch Gen Psychiatry       Date:  2012-12

3.  Benefits of cognitive remediation and supported employment for schizophrenia patients with poor community functioning.

Authors:  Morris D Bell; Kee-Hong Choi; Christina Dyer; Bruce E Wexler
Journal:  Psychiatr Serv       Date:  2014-04-01       Impact factor: 3.084

4.  Motivation and its relationship to neurocognition, social cognition, and functional outcome in schizophrenia.

Authors:  David E Gard; Melissa Fisher; Coleman Garrett; Alexander Genevsky; Sophia Vinogradov
Journal:  Schizophr Res       Date:  2009-09-23       Impact factor: 4.939

5.  Apathy but not diminished expression in schizophrenia is associated with discounting of monetary rewards by physical effort.

Authors:  Matthias N Hartmann; Oliver M Hager; Anna V Reimann; Justin R Chumbley; Matthias Kirschner; Erich Seifritz; Philippe N Tobler; Stefan Kaiser
Journal:  Schizophr Bull       Date:  2014-07-22       Impact factor: 9.306

6.  Negative symptoms of schizophrenia are associated with abnormal effort-cost computations.

Authors:  James M Gold; Gregory P Strauss; James A Waltz; Benjamin M Robinson; Jamie K Brown; Michael J Frank
Journal:  Biol Psychiatry       Date:  2013-02-07       Impact factor: 13.382

7.  Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects.

Authors:  Eri Nakagami; Bin Xie; Maanse Hoe; John S Brekke
Journal:  Schizophr Res       Date:  2008-08-19       Impact factor: 4.939

8.  Effort, anhedonia, and function in schizophrenia: reduced effort allocation predicts amotivation and functional impairment.

Authors:  Deanna M Barch; Michael T Treadway; Nathan Schoen
Journal:  J Abnorm Psychol       Date:  2014-05

9.  A review of reward processing and motivational impairment in schizophrenia.

Authors:  Gregory P Strauss; James A Waltz; James M Gold
Journal:  Schizophr Bull       Date:  2013-12-27       Impact factor: 9.306

10.  Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia.

Authors:  Ryan D Ward; Eleanor H Simpson; Vanessa L Richards; Gita Deo; Kathleen Taylor; John I Glendinning; Eric R Kandel; Peter D Balsam
Journal:  Neuropsychopharmacology       Date:  2012-03-14       Impact factor: 7.853

View more
  33 in total

1.  Assessment of a glycine uptake inhibitor in animal models of effort-related choice behavior: implications for motivational dysfunctions.

Authors:  Samantha E Yohn; Daniela Alberati; Merce Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2017-01-12       Impact factor: 4.530

2.  Clarifying the overlap between motivation and negative symptom measures in schizophrenia research: A meta-analysis.

Authors:  Lauren Luther; Melanie W Fischer; Ruth L Firmin; Michelle P Salyers
Journal:  Schizophr Res       Date:  2018-12-19       Impact factor: 4.939

Review 3.  Inflammation Effects on Motivation and Motor Activity: Role of Dopamine.

Authors:  Jennifer C Felger; Michael T Treadway
Journal:  Neuropsychopharmacology       Date:  2016-08-02       Impact factor: 7.853

4.  Social motivation in schizophrenia: The impact of oxytocin on vigor in the context of social and nonsocial reinforcement.

Authors:  Daniel Fulford; Michael Treadway; Joshua Woolley
Journal:  J Abnorm Psychol       Date:  2018-01

5.  Ecological momentary assessment of negative symptoms in schizophrenia: Relationships to effort-based decision making and reinforcement learning.

Authors:  Erin K Moran; Adam J Culbreth; Deanna M Barch
Journal:  J Abnorm Psychol       Date:  2016-11-28

6.  Understanding the Association Between Negative Symptoms and Performance on Effort-Based Decision-Making Tasks: The Importance of Defeatist Performance Beliefs.

Authors:  L Felice Reddy; William P Horan; Deanna M Barch; Robert W Buchanan; James M Gold; Stephen R Marder; Jonathan K Wynn; Jared Young; Michael F Green
Journal:  Schizophr Bull       Date:  2018-10-17       Impact factor: 9.306

7.  The relationships among aberrant salience, reward motivation, and reward sensitivity.

Authors:  Suzanne R Neumann; Richard J Linscott
Journal:  Int J Methods Psychiatr Res       Date:  2018-04-24       Impact factor: 4.035

8.  Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms.

Authors:  L Felice Reddy; William P Horan; Deanna M Barch; Robert W Buchanan; Eduardo Dunayevich; James M Gold; Naomi Lyons; Stephen R Marder; Michael T Treadway; Jonathan K Wynn; Jared W Young; Michael F Green
Journal:  Schizophr Bull       Date:  2015-07-03       Impact factor: 9.306

Review 9.  A meta-analytic review of self-reported, clinician-rated, and performance-based motivation measures in schizophrenia: Are we measuring the same "stuff"?

Authors:  Lauren Luther; Ruth L Firmin; Paul H Lysaker; Kyle S Minor; Michelle P Salyers
Journal:  Clin Psychol Rev       Date:  2018-04-07

10.  Self-assessment of social cognitive ability in individuals with schizophrenia: Appraising task difficulty and allocation of effort.

Authors:  Danielle Cornacchio; Amy E Pinkham; David L Penn; Philip D Harvey
Journal:  Schizophr Res       Date:  2016-09-29       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.